Optimizing Frontline Treatment Approaches in EGFRm Metastatic NSCLC - Episode 14
Looking Ahead: Unmet Needs and Future Directions in the Treatment of Advanced EGFR-Mutant NSCLC
Panelists discuss how despite recent advances in first-line treatments, unmet needs remain. These include better personalized care, community education, understanding resistance mechanisms, central nervous system (CNS) metastases management, and development of novel therapies such as antibody-drug conjugates.
Future Perspectives and Unmet Needs
Main Discussion Topics:
- Remaining gaps in knowledge and unmet needs in EGFR-mutant non–small cell lung cancer (NSCLC)
- Novel therapies and treatment strategies on the horizon
- Challenges in treatment beyond first-line settings
Key Points for Physicians:
- Continued need for education and personalized care approaches
- Mechanisms of resistance to combination therapies remain an important area of investigation
- Management of refractory CNS metastatic disease remains challenging
Notable Insights:
Emerging therapeutic approaches of interest include antibody-drug conjugates, protein degraders (proteolysis-targeting chimeras), radioconjugates, and strategies to enhance immunotherapy responses.
Clinical Significance:
Although significant advances have been made in first-line therapy for EGFR-mutant NSCLC, ongoing research is needed to address resistance mechanisms and improve outcomes in subsequent treatment lines.
Related Content:
